Ekso Bionics (NASDAQ:EKSO) Now Covered by StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the stock.

EKSO has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Ekso Bionics in a research note on Tuesday, July 30th. Lake Street Capital began coverage on Ekso Bionics in a research report on Monday, June 24th. They issued a “buy” rating and a $2.50 price objective on the stock.

Ekso Bionics Trading Down 3.2 %

NASDAQ:EKSO opened at $1.19 on Tuesday. Ekso Bionics has a 52-week low of $0.62 and a 52-week high of $3.13. The company has a quick ratio of 1.77, a current ratio of 2.42 and a debt-to-equity ratio of 0.36. The stock has a fifty day simple moving average of $1.12 and a 200-day simple moving average of $1.21. The company has a market capitalization of $21.95 million, a PE ratio of -1.23 and a beta of 1.45.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, July 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. The business had revenue of $4.95 million for the quarter, compared to analyst estimates of $5.34 million. During the same quarter in the previous year, the firm posted ($0.31) EPS. On average, equities research analysts expect that Ekso Bionics will post -0.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC raised its holdings in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the period. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.